ERBB2 and breast cancer: When the 40 breast cancer cell lines were stratified into HER2+/ER+ and TNBC groups and then stratified again via their therapeutic response to IBL-302, it was shown in the responsive groups that PIM 1 expression was elevated, PIM 3 expression was decreased and MYC amplification significantly reduced when compared with the non-responsive groups (Supplementary Fig. 2A–C).